By: Mandy Jackson
Haisco Pharmaceutical out-licensed a preclinical drug for inflammatory diseases to Sentivera for $75.89m up front, including a 17.5% stake in the startup backed by ARCH Venture Partners and Population Health Partners.
Geo Focus
Coverage Attributes:
Beta
Informative:
58
%
Data Driven:
18
%
Interviews Q&as:
9
%
Events:
7
%
Reviews:
2
%
Themes Covered:
Not enough data
Pitching Insights
Mandy Jackson's coverage focuses on the healthcare and pharmaceutical industry, particularly on drug development, FDA approvals, and biopharmaceutical companies. Additionally, she covers financial aspects related to these sectors.
Given her focus on press releases and private sector announcements, Mandy would likely be responsive to pitches that provide exclusive insights into new drug developments or financial activities within the healthcare and pharmaceutical industries. She may also be interested in expert commentary regarding regulatory changes impacting drug development or financial trends affecting biopharmaceutical companies.
While no specific geographic focus is mentioned for Mandy's coverage area, it’s important to note that her articles cover global developments in the healthcare and pharmaceutical sectors as well as finance-related topics relevant to these industries.
This information evolves through artificial intelligence and human feedback. Improve this profile .
Journalists With Similar Coverage:
Based on similarity of content.
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
Publications
Most recent topics
Not enough data
